In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

Covid has caused serious amounts of chronic illness. Research advances may help not only people facing chronic illnesses ...

Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...

Vaccine maker Moderna announced today that the US Food and Drug Administration (FDA) has granted full approval of its ...

As part of a person's first line of defense against viruses and other microbes that cause illness and disease, a whole network of proteins and other molecules detect and respond to intruders, which ...

Pepper the cat, whose owner works at the University of Florida, gathered a specimen containing a never-before-seen virus for ...

The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

Fresh off of the heels of a shakeup at the CDC over vaccine recommendations, many Americans still question the necessity and safety of COVID-19 vaccines for young children.

With the 2025 influenza season starting earlier than usual, the NICD urges South Africans to stay vigilant against seasonal ...

A new variant of COVID that makes up more than 30% of cases in the UK and more than 42% of cases in Spain more easily beats ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...